NOVARTIS Australia's Cosentyx (secukinumab) has been listed on the PBS for the treatment of Australian adult patients with active moderate-to-severe hidradenitis suppurativa (HS), who have had an inadequate response to conventional systemic HS therapy.
Cosentyx is a recombinant fully human monoclonal antibody that selectively inhibits interleukin-17A.
It works by selectively neutralising one of the key proinflammatory cytokines associated with HS, to bring symptomatic relief for patients as early as four weeks after initial treatment.
HS, also called acne inversa, is a chronic inflammatory skin disease where painful lesions appear beneath the skin.
Pharmacists can learn more about this PBS medication by CLICKING HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Jun 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Jun 24
